![Synthesis of ursodeoxycholic acid from plant-source (20S)-21-hydroxy-20-methylpregn-4-en-3-one - ScienceDirect Synthesis of ursodeoxycholic acid from plant-source (20S)-21-hydroxy-20-methylpregn-4-en-3-one - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0039128X20300258-ga1.jpg)
Synthesis of ursodeoxycholic acid from plant-source (20S)-21-hydroxy-20-methylpregn-4-en-3-one - ScienceDirect
![Figure 1 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar Figure 1 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8c083303490d24d37a88317beed8b18de95ce5a0/2-Figure1-1.png)
Figure 1 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/c1eccfbc-fb19-4d1c-8f17-a5c255873359/gr1_lrg.jpg)
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology
![24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ - JHEP Reports 24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ - JHEP Reports](https://www.jhep-reports.eu/cms/asset/61a57acb-b941-4763-b7fd-0fffccb20f18/ga1.jpg)
24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ - JHEP Reports
![99697-24-2 | 24-Nor Ursodeoxycholic Acid | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid; | C₂₃H₃₈O₄ | TRC 99697-24-2 | 24-Nor Ursodeoxycholic Acid | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid; | C₂₃H₃₈O₄ | TRC](https://www.trc-canada.com/prod-img/N865300.png)
99697-24-2 | 24-Nor Ursodeoxycholic Acid | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid; | C₂₃H₃₈O₄ | TRC
![Biomolecules | Free Full-Text | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart Biomolecules | Free Full-Text | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart](https://www.mdpi.com/biomolecules/biomolecules-08-00159/article_deploy/html/images/biomolecules-08-00159-g003.png)
Biomolecules | Free Full-Text | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/794e1771-28bd-4544-bad6-677c5edad3c5/gr3_lrg.jpg)
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology
![24-Nor Ursodeoxycholic Acid-d5 | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5; 3α,7β-Dihydroxy-24-nor-5β-cholan-23-oic Acid-d5; Norursodeoxycholic Acid-d5; | C₂₃H₃₃D₅O₄ | TRC 24-Nor Ursodeoxycholic Acid-d5 | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5; 3α,7β-Dihydroxy-24-nor-5β-cholan-23-oic Acid-d5; Norursodeoxycholic Acid-d5; | C₂₃H₃₃D₅O₄ | TRC](https://www.trc-canada.com/prod-img/N865302.png)
24-Nor Ursodeoxycholic Acid-d5 | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5; 3α,7β-Dihydroxy-24-nor-5β-cholan-23-oic Acid-d5; Norursodeoxycholic Acid-d5; | C₂₃H₃₃D₅O₄ | TRC
![24-Nor Ursodeoxycholic Acid-d5 (major) Acyl-b-D-glucuronide | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5 1-O-Acyl-β-D-glucuronide; 24-Nor Ursodeoxycholic Acid-d5 1-O-Acyl-β-D-glucuronide; | C₂₉H₄₁D₅O₁₀ | TRC 24-Nor Ursodeoxycholic Acid-d5 (major) Acyl-b-D-glucuronide | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5 1-O-Acyl-β-D-glucuronide; 24-Nor Ursodeoxycholic Acid-d5 1-O-Acyl-β-D-glucuronide; | C₂₉H₄₁D₅O₁₀ | TRC](https://www.trc-canada.com/prod-img/N865312.png)
24-Nor Ursodeoxycholic Acid-d5 (major) Acyl-b-D-glucuronide | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5 1-O-Acyl-β-D-glucuronide; 24-Nor Ursodeoxycholic Acid-d5 1-O-Acyl-β-D-glucuronide; | C₂₉H₄₁D₅O₁₀ | TRC
![Mechanism of action of three potential therapeutic drugs-ursolic acid,... | Download Scientific Diagram Mechanism of action of three potential therapeutic drugs-ursolic acid,... | Download Scientific Diagram](https://www.researchgate.net/publication/311917773/figure/fig1/AS:443902764294144@1482846074276/Mechanism-of-action-of-three-potential-therapeutic-drugs-ursolic-acid.png)
Mechanism of action of three potential therapeutic drugs-ursolic acid,... | Download Scientific Diagram
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/8ddb887f-c37c-4d1a-bfeb-c50225ec9677/gr6.jpg)